| |
Unmanipulated PBMCs
|
Non-adherent fraction
|
p
|
|---|
| |
Leukocyte subpopulations
| |
|---|
|
CD14+ cells
|
47.8% (36.0 - 55.0)
|
2.1% (1.3 - 6.1)
|
0.005
|
|
T lymphocytes (CD3+)
|
24.0% (18.0 - 37.1)
|
69.9% (31.9 - 79.2)
|
0.007
|
|
CTLs (CD3 + CD8+)
|
17.7% (6.8 - 25.1)
|
35.2% (23.8 - 45.2)
|
0.009
|
|
Helper T cells (CD3 + CD4+)
|
12.5% (11.4 - 19.4)
|
19.3% (16.6 - 29.6)
|
0.208
|
|
Viability (7-AAD-)
|
98.0% (95.6 - 98.5)
|
96.0% (93.4 - 97.8)
|
0.066
|
| |
PM staining: specific and non-specific binding
| |
|
CMV-specific CTLs (CD3 + CD8 + PM+)
|
0.14% (0.06 - 0.62)
|
0.65% (0.24 - 1.51)
|
0.003
|
|
Non-specific PM binding (CD8-PM+)
|
0.56% (0.41 - 0.86)
|
0.16% (0.12 - 0.37)
|
0.003
|
| |
CMV-specific CTL isolation
| |
|
Purity
|
20.8% (6.9 - 61.7)
|
76.0% (32.7 - 83.7)
|
0.043
|
|
Yield
|
38.6% (32.9 - 44.8)
|
42.1% (23.4 - 84.1)
|
0.893
|
- Cell subsets, CMV-specific CTLs and non-specific PM staining were analyzed in the unmanipulated PBMC sample and in the non-adherent cells (n = 11). CMV-specific CTLs were isolated from unmanipulated PBMCs and non-adherent fraction, and purity and yield of the obtained cellular product were determined (n = 5). Comparison was done with the Wilcoxon signed-rank test and significance level was fixed to p < 0.05.
